Culture Biosciences Taps Industry Veteran to Drive Hardware and SaaS Growth

SAN FRANCISCO, CA – April 14, 2026 – Culture Biosciences, a company at the vanguard of bioprocess development technology, today announced a significant strategic enhancement to its leadership by appointing Mike Stapleton to its Board of Directors. The move signals a focused effort to accelerate the commercialization of its Stratyx hardware platform and the expansion of its AI-powered Console SaaS offering, capitalizing on momentum from its recent Series C financing.

Stapleton, a life sciences executive with over three decades of experience, joins the company at a pivotal moment. His appointment is part of a planned governance transition designed to equip Culture with the specific expertise needed to navigate its next phase of aggressive market expansion and technological innovation.

A Strategic Play for Commercial Scale-Up

Mike Stapleton’s extensive career is a roadmap of successful digital transformation and commercialization initiatives across the life sciences sector. His track record includes senior executive roles at industry giants such as Merck, where he served as VP and CIO of R&D IT, and PerkinElmer, where he led the informatics business as General Manager. His experience also spans leadership positions at Life Technologies, Accelrys, and as a Managing Director at Accenture, where he managed the North America Life Sciences innovation practice.

Currently serving as Chief Business Officer at QbDVision, Stapleton has consistently focused on building scalable platforms that merge data science with biology. This deep expertise in taking complex life science instruments and software to market on a global scale is precisely what Culture Biosciences sought as it prepares for a major commercial push.

"This Board evolution positions Culture Biosciences with the precise expertise we need as we commercialize our hardware platform and rapidly scale our AI capabilities through our Console SaaS offering," said Chris Williams, CEO of Culture Biosciences. "Mike brings decades of experience taking life science instruments and software to market at global scale. We are fortunate to have him as a partner at this stage of our journey."

The Integrated Platform Driving Bioprocess Innovation

At the heart of Culture's strategy is a unique, tightly integrated system of hardware and software designed to address long-standing inefficiencies in bioprocess development. The company’s flagship products, the Stratyx hardware platform and Console SaaS offering, work in concert to make bioprocessing data more accessible, contextual, and actionable.

The Stratyx 250 Bioreactor Platform, launched in April 2025, represents the next generation of bioreactor technology. It features a modular, cart-based design for maximum flexibility, allowing labs to easily reconfigure and relocate capacity without major infrastructure changes. By leveraging single-use technology, the platform promises a 16% lower total cost per run compared to traditional systems by eliminating cleaning and reducing downtime. The company reports that clients can achieve up to 25% faster development timelines and a 30% improvement in scale-up success.

Complementing the hardware is Culture Console, a cloud-native software platform that enables researchers to remotely design, monitor, and analyze experiments 24/7. The platform provides real-time data visualization and is being enhanced with advanced AI and machine learning capabilities. Through a collaboration with Google Cloud, Culture is integrating tools like Gemini AI, BigQuery, and Looker to enable predictive modeling, automated process control, and natural language data queries.

This powerful combination caught Stapleton's attention. "Culture Biosciences has built something genuinely differentiated — a tightly integrated hardware and software platform that addresses unmet needs in bioprocess development," Stapleton stated. "I'm excited to help the team capitalize on that foundation and bring these tools to a wider market."

Riding the Wave of Digital Transformation in Biopharma

Culture Biosciences' strategic moves are perfectly timed with a seismic shift occurring across the biopharmaceutical industry. The global bioprocess technology market, valued at over $44 billion in 2025, is projected to surge to approximately $164 billion by 2034, fueled by a compound annual growth rate exceeding 15%. This expansion is driven by the increasing demand for complex biologics, vaccines, and cell and gene therapies.

To meet this demand, the industry is rapidly moving away from fragmented, analog lab systems toward unified digital platforms. Key trends include the adoption of automation, AI/ML, and the Internet of Things (IoT) to create integrated systems that offer real-time monitoring and control. Single-use technologies (SUTs) are also seeing explosive growth, with the market projected to nearly double to $11.2 billion by 2029. Culture's integrated platform, combining SUT-based hardware with a sophisticated cloud and AI backend, directly addresses these converging market needs, positioning the company as a key enabler of the digital-first bioprocessing lab of the future.

Governance for Growth Following Series C

The appointment of Stapleton is a key part of a broader, deliberate evolution of Culture's governance structure following its successful Series C fundraising round in December 2025. The financing, led by existing investors including Northpond Ventures and Synthesis Capital, was secured specifically to fund the commercial expansion of the Stratyx 250 and the continued AI development within the Console ecosystem.

This board transition includes the departure of co-founder Will Patrick, whose foundational vision was instrumental in the company's creation in 2016. Additionally, Beth Webb, who served a two-year term as an Independent Director during a period of pivotal growth, will transition to a role as a Strategic Advisor to the company. These changes reflect a mature, forward-looking approach to corporate governance, ensuring the board's composition aligns with the company's immediate strategic imperatives: scaling operations and capturing significant market share. By bringing in a commercialization heavyweight like Stapleton, Culture Biosciences is signaling to investors and the market that it is fully equipped and ready to execute on its mission to revolutionize bioprocess development.